Scholay

学术搜索 · AI 审稿 · LaTeX 协作

Oliver R. Mikse

机构：Io Therapeutics (United States), Foghorn Therapeutics (United States)

发表论文 68 篇 · 总被引 1909 次 · h-index 10

代表论文

  • Abstract A049: Investigation of FHD-609, a potent degrader of BRD9, in preclinical models of acute myeloid leukemia (AML) (2023 · Molecular Cancer Therapeutics · 被引 5)
  • Abstract A064: Establishing the cellular and molecular impacts of the dual BRM/BRG1 inhibitor FHD-286 on pre-clinical models of non-small cell lung cancer (NSCLC) (2023 · Molecular Cancer Therapeutics · 被引 2)
  • Abstract A058: Investigating the molecular role of BRD9 in synovial sarcoma (2023 · Molecular Cancer Therapeutics)
  • Abstract A079: FHD286 is a BRG1/BRM ATPase inhibitor showing efficacy in NSCLC models and is applicable to NSCLC patients both as a single agent treatment and in combination with current standards of care (2023 · Molecular Cancer Therapeutics)
  • Data from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors (2023)
  • Data from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors (2023)